Does Christiana Care Health System Cover Dupixent?

What Christiana Care Health System Actually Is (and What It Covers)

Christiana Care Health System is a large Delaware-based nonprofit academic health system, not an insurance company. The distinction matters enormously when you are trying to answer a coverage question. Christiana Care operates hospitals, outpatient clinics, and employed physician practices. It does not underwrite or administer health insurance plans in the traditional sense, meaning it does not decide which drugs your plan pays for.

Your actual insurer, whether that is a commercial carrier like Highmark Blue Cross Blue Shield of Delaware, Aetna, UnitedHealthcare, a Delaware Medicaid managed care organization, or a Medicare Part D plan, controls whether Dupixent appears on its formulary and under what conditions it will pay.

Why People Confuse the Health System with an Insurer

Some large health systems do operate their own insurance products. Christiana Care has historically participated in and partnered with regional plans but does not itself sell coverage products to the general public. If your employer-sponsored plan is administered through a Delaware-based insurer and your care is delivered at Christiana Care facilities, coverage decisions still originate with the insurer, not the hospital system.

How to Find Your Actual Payer

Check the back of your insurance card. The plan name, phone number, and group number identify who controls your formulary. When Christiana Care clinicians submit a prior authorization for Dupixent, they submit it to that external payer using your member ID.

What Is Dupixent and Why Does It Require Special Authorization?

Dupixent (dupilumab) is a fully human monoclonal antibody that blocks the shared receptor subunit for interleukin-4 and interleukin-13, two cytokines central to type 2 inflammatory disease. The FDA first approved dupilumab for moderate-to-severe atopic dermatitis in adults in March 2017 and has since expanded the label to include adolescents and children as young as 6 months for atopic dermatitis, adults and children aged 6 and older with moderate-to-severe asthma, adults with chronic rhinosinusitis with nasal polyps (CRSwNP), adults and adolescents with eosinophilic esophagitis (EoE), adults with prurigo nodularis, and adults with inadequately controlled COPD driven by type 2 inflammation. 1

Clinical Efficacy Data That Insurers Cite in Coverage Policies

Payers base coverage criteria on the same trial data that supported FDA approval. In the SOLO 1 and SOLO 2 trials (combined N=1,379), dupilumab 300 mg every two weeks produced an IGA 0/1 (clear or almost clear skin) response rate of 38% versus 10% for placebo at 16 weeks (P<0.001). 2 The LIBERTY AD CHRONOS trial (N=740) extended follow-up to 52 weeks and confirmed durability, with 40% of patients on dupilumab plus low-potency topical corticosteroids achieving EASI-75 at one year versus 12% on placebo plus topical corticosteroid (P<0.001). 3

For asthma, the LIBERTY ASTHMA QUEST trial (N=1,902) showed dupilumab 200 mg every two weeks reduced annualized severe exacerbation rates by 47.7% versus placebo in patients with baseline eosinophils ≥150 cells/mcL (P<0.001). 4

For EoE, PART A and PART B of the EoE LIBERTY trial (N=240) showed 59% of patients on dupilumab 300 mg weekly achieved histologic remission (<6 eosinophils per high-power field) versus 6% on placebo. 5

Why Biologics Trigger Prior Authorization

Dupixent's list price, roughly $3,800 per 28-day supply, means payers impose step-therapy requirements to confirm that less expensive treatments have been tried first. The American Academy of Dermatology's 2023 guidelines state that dupilumab is appropriate for patients "with moderate-to-severe atopic dermatitis inadequately controlled with topical therapies or for whom topical therapies are not advisable." 6 Most payer policies mirror this language almost exactly.

How Prior Authorization Works for Dupixent at Christiana Care

When a Christiana Care dermatologist, allergist, or pulmonologist decides dupilumab is medically appropriate, the prescribing team submits a prior authorization (PA) request to your insurer. The PA packet typically takes 5 to 15 business days to adjudicate, though urgent PA requests can be processed within 72 hours under state and federal rules. 7

Documents Typically Required

• Diagnosis code (ICD-10) and severity documentation, usually a validated score such as EASI, IGA, NRS, or AQLQ
• Records showing failure of at least two topical corticosteroids at adequate potency and duration (generally 4 to 8 weeks per agent)
• For asthma: evidence of uncontrolled disease on an inhaled corticosteroid plus a long-acting beta-agonist
• For EoE: endoscopy report with biopsy confirming eosinophil count ≥15 per high-power field and documented failure of a proton pump inhibitor
• Letter of medical necessity from the prescribing physician

What Happens After Submission

Your insurer issues one of three responses: approval (with a coverage duration of typically 6 to 12 months before renewal), denial, or a request for additional information. If denied, federal law and most state laws give you the right to an internal appeal and then an external independent review. The Centers for Medicare and Medicaid Services reports that external review overturned insurer denials in roughly 40 to 60% of cases where complete documentation was provided. 8

The Role of the Christiana Care Specialty Pharmacy Team

Many Christiana Care-affiliated practices work with a specialty pharmacy hub that manages PA submissions, tracks appeal deadlines, and coordinates bridge supply through Sanofi's Dupixent MyWay program while a PA is pending. Ask your prescriber's office explicitly whether they use a hub service, because this shortens the average time to first dose by approximately 7 to 10 days based on specialty pharmacy benchmark data.

Dupixent Formulary Status on Common Delaware-Area Plans

Because Christiana Care serves patients across Delaware, southern New Jersey, and northeastern Maryland, the plans most commonly encountered at its facilities include the following categories. Formulary tiers change annually during open enrollment, so verify your current plan year's formulary directly with your insurer.

Commercial Plans

Most major commercial carriers place dupilumab on Tier 4 or Tier 5 (specialty tier), meaning cost-sharing before manufacturer copay assistance could run $500 to $1,500 per fill. Highmark Blue Cross Blue Shield of Delaware, the largest commercial insurer in the state, covers dupilumab for its FDA-approved indications subject to PA and step therapy. UnitedHealthcare and Aetna follow similar frameworks and update their coverage policies annually in alignment with FDA label expansions. 9

Delaware Medicaid (Diamond State Health Plan)

Delaware Medicaid covers dupilumab for atopic dermatitis and asthma for enrollees who meet the PA criteria. The state's preferred drug list, updated quarterly by the Delaware Division of Medicaid and Medical Assistance, governs specific step-therapy requirements. Providers must document failure of two topical agents for dermatology indications or two controller inhalers for asthma before the plan approves the biologic. 10

Medicare Part D

Medicare Part D plans must cover dupilumab under the protected class provisions when it is prescribed for an FDA-approved indication. Standard Part D cost-sharing in the catastrophic coverage phase dropped to $0 out-of-pocket for covered drugs starting January 1, 2025, under the Inflation Reduction Act, which substantially changes the math for Medicare beneficiaries who previously faced high specialty tier costs. 11

What to Do if Your Plan Denies Dupixent Coverage

A denial is not a final answer. Payers deny biologics frequently on first submission, often because documentation was incomplete rather than because the drug is categorically excluded. The process below applies regardless of whether your care is delivered at Christiana Care or another Delaware provider.

Step 1: Obtain the Denial Letter and Reason Code

Federal law requires your insurer to provide a written denial with the specific clinical or administrative reason. Common denial reasons for dupilumab include "step therapy not completed," "diagnosis not covered under this indication," and "not medically necessary per plan criteria."

Step 2: File an Internal Appeal Within the Deadline

Most plans allow 60 to 180 days from the denial date to file an internal appeal. Your Christiana Care prescriber should provide an updated letter of medical necessity that directly addresses the denial reason, including peer-reviewed citations and relevant validated severity scores. The AAD recommends including objective disease severity scores (EASI ≥16 for moderate-to-severe disease) in every appeal letter. 12

Step 3: Request Expedited External Review if Urgent

If your condition is severe and the internal appeal is taking too long, you can request an expedited external independent review in parallel. Under the Affordable Care Act, external reviewers must be independent of your insurer. 13

Step 4: Apply for Bridge Supply Through Dupixent MyWay

While an appeal is in progress, Sanofi's Dupixent MyWay program can provide free medication to patients who are uninsured, underinsured, or whose plan has denied coverage and who meet income thresholds. The program covers 100% of drug cost for eligible patients earning up to 600% of the federal poverty level. 14

Dupixent Cost Without Insurance and Assistance Programs

Without any insurance or assistance, dupilumab 300 mg prefilled syringes (a 28-day supply for most atopic dermatitis dosing) carry a list price of approximately $3,700 to $3,900 depending on the pharmacy. Few patients pay this amount.

Manufacturer Copay Card (Commercially Insured Patients)

Commercially insured patients may use the Dupixent MyWay copay card, which can reduce out-of-pocket costs to as low as $0 per month for eligible patients. This card cannot be used by patients on Medicare, Medicaid, or other government-funded insurance due to federal anti-kickback statute restrictions. 15

340B Drug Pricing

Some Christiana Care-affiliated outpatient clinics qualify as 340B-covered entities, which means they can purchase certain drugs, potentially including dupilumab, at significantly reduced 340B ceiling prices. Patients receiving care at qualifying sites may see reduced costs depending on how the specific clinic structures its pharmacy benefit. Ask your care team whether the specific Christiana Care location where you receive treatment participates in 340B. 16

State Pharmaceutical Assistance Programs

Delaware's Pharmaceutical Assistance Program (DPAP) provides supplemental drug coverage for Delaware residents aged 65 and older with income at or below 200% of the federal poverty level. For working-age adults, Delaware's Healthy Children and Adults program under Medicaid may cover dupilumab if the individual qualifies for expanded Medicaid under the ACA. 17

Conditions Dupixent Treats: Ensuring Your Diagnosis Is Coded Correctly

Coverage denials sometimes stem from incorrect ICD-10 coding rather than a formulary exclusion. Dupilumab is FDA-approved for the following conditions, each with its own ICD-10 code that must appear on the PA submission. 18

Atopic Dermatitis

ICD-10 code L20.89 (other atopic dermatitis) or L20.9 (atopic dermatitis, unspecified) is used for adults and children. The label covers moderate-to-severe disease inadequately controlled with topical therapies or for whom topicals are not advisable. The EASI score, IGA, and BSA percentage are the three most commonly referenced severity metrics in PA forms. 19

Asthma

ICD-10 code J45.51 (severe persistent asthma with acute exacerbation) or J45.50 (severe persistent asthma, uncomplicated) is appropriate for most PA submissions. Payers commonly require documented peripheral blood eosinophils ≥150 cells/mcL or elevated FeNO as a biomarker of type 2 inflammation. 20

Chronic Rhinosinusitis with Nasal Polyps

ICD-10 code J33.9. PA requirements typically include CT sinus documentation showing bilateral polyp burden and failure of intranasal corticosteroids for at least 4 weeks. 21

Eosinophilic Esophagitis

ICD-10 code K20.0. Endoscopy with biopsy showing ≥15 eosinophils per high-power field after an 8-week PPI trial is the standard documentation requirement. 22

Prurigo Nodularis

ICD-10 code L28.1. This indication received FDA approval in September 2022, and some older plan coverage policies have not yet been updated to reflect it. If your plan denies dupilumab for prurigo nodularis citing "indication not covered," cite the FDA approval letter directly in your appeal. 23

Talking to Your Christiana Care Provider About Dupixent

Your prescriber's office handles the administrative work of PA submission, but your involvement matters. Bring the following to your appointment so the PA process starts with complete documentation on day one.

Bring a written log of every topical corticosteroid or other prescription topical treatment you have used, including approximate dates, potency class, and why the treatment was stopped (insufficient response, side effects, or adherence problems). This contemporaneous record is substantially more persuasive in a PA letter than a general statement that "topicals failed."

Bring pharmacy printouts showing fill dates for past prescriptions. Insurance systems cross-reference claim histories, and documented pharmacy claims are harder to dispute than patient self-report alone.

Ask your provider whether your case qualifies for a peer-to-peer review call with the insurer's medical director. These calls, where your treating clinician speaks directly with the plan's reviewing physician, reverse denials in a meaningful proportion of cases, particularly when the prescriber can cite trial data (such as the CHRONOS 52-week durability data) and your specific severity scores simultaneously. 24

Key Safety Considerations That May Affect Coverage Decisions

Insurance medical policies sometimes reference safety data when setting coverage criteria. Dupilumab's safety profile in clinical trials was generally favorable, with conjunctivitis (9-10% versus 2-3% placebo in atopic dermatitis trials) and injection-site reactions (10% versus 6% placebo) as the most common adverse events. 25 No increased risk of serious infections was observed in SOLO 1, SOLO 2, or CHRONOS, which distinguishes dupilumab from some other biologics that require negative tuberculosis testing before initiation.

The FDA prescribing information does not list any black box warnings for dupilumab. Payers cannot cite a safety exclusion as a reason to deny coverage for an on-label indication, though they can and do require safety monitoring documentation for renewal authorizations.

For patients with a concurrent live vaccine need, the FDA label recommends completing live vaccinations before starting dupilumab, as data on live vaccines during dupilumab therapy are limited. The CDC Advisory Committee on Immunization Practices provides guidance on biologic-specific vaccination timing. 26